Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2021-11-23 Regulatory Filings
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-11-23 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3 under the Securities Act of 1933. It is a correspondence related to a capital raising filing, specifically a registration statement for securities issuance. The document is short (1107 characters) and is a formal request rather than a report or financial statement. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-11-18 English
Regulatory Filings 2021
Regulatory Filings Classification · 70% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Due to the lack of identifiable information and the inability to determine the nature of the document, it cannot be classified into any specific filing category based on the given text. According to the fallback rule, documents that do not neatly fit into any category should be classified as Regulatory Filings (RNS).
2021-11-18 English
FORM 4
Director's Dealing
2021-11-16 English
FORM 4
Director's Dealing
2021-11-16 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for public offering. It includes a prospectus for offering common stock, preferred stock, debt securities, and warrants up to $200 million. The document is a detailed registration statement and prospectus, not an announcement or summary. It is not a financial report, earnings release, or management discussion. It is clearly a capital raising filing related to securities issuance and financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, consistent with a capital/financing update filing.
2021-11-10 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.